Study of SYS6041 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called SYS6041 for people with certain advanced cancers that have not responded to standard treatments. It targets a protein called FRα found on some tumor cells, which may help the drug attack the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You need to be generally well enough to care for yourself (ECOG score 0 or 1).
- You must have a tumor that can be measured on scans.
- You need to provide a tumor tissue sample for FRα testing.
- If you have ovarian, endometrial, lung, or breast cancer that has progressed after standard therapy, you may qualify for the first part of the study.
- You must agree to use reliable contraception during and after the study if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug (called SYS6051) in people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if the drug is safe and how well it works, and it might help control your cancer.
This trial is testing an investigational drug called SYS6077 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. The goal is to find out if this drug is a safe option for patients who have run out of other choices.
This study tests a new drug called SYS6043, alone or with other treatments, for advanced solid tumors that have not responded to standard therapy. It may offer a new option for patients with certain types of ovarian, fallopian tube, or primary peritoneal cancer.
This trial tests a new drug that may help people with advanced solid tumors, including liver, stomach, and brain cancers. It is for patients whose cancer has not responded to standard treatments or who cannot have them. The study aims to find the right dose and check safety and effectiveness.
This trial tests a new drug, SYN608, in people with advanced or metastatic solid tumors, including breast and ovarian cancer, who have run out of standard treatment options. The drug targets tumors with BRCA mutations or other DNA repair problems, which may make them more sensitive to this treatment.
This study is testing a new drug called SHR-1049 for people with advanced solid tumors (cancers that have spread). It looks at safety, how the drug moves through the body, and whether it helps shrink tumors. You may be eligible if you have tried standard treatment without success or no standard treatment exists.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.